Advancing a class on top of statins
Investors & Media

RSS Content

Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) and NASH to be Rescheduled

LIVONIA, Mich., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that due to a family emergency of one of the a panel members, it will need to reschedule the expert panel call discussing pediatric nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that was scheduled for Wednesday, February 28.  A new date and time for the expert panel call will be announced as soon as possible.

About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH.  The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors.  Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD.  Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151.  Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit for more information.

Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987

Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.

Primary Logo

Gemphire Therapeutics Inc.